Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity

Objective: To investigate chest wall pain in patients with peripheral early stage lung cancer treated with stereotactic ablative radiotherapy (SABR), and to identify factors predictive of Common Terminology Criteria of Adverse Events Grade 2 + chest wall pain. Methods: Patients who received 55Gy in five fractions were included. A chest wall structure was retrospectively defined on planning scans, and chest wall dosimetry and tumour-related factors recorded. Logistic regression was performed to identify factors predictive of >= Grade 2 chest wall pain. Results: 182 patients and 187 tumours were included. There were 20 (10.9%) episodes of >= Grade 2 chest wall pain. Multivariate logistic regression demonstrated that the maximum dose received by 1 cm(3) of chest wall (D(max)1cm(3)) and tumour size were significant predictors of >= Grade 2 chest wall pain [D(max)1cm(3) odds ratio : 1.104, 95% confidence interval : 1.012-1.204, p = 0.025; tumour size (mm) odds ratio : 1.080, 95% confidence interval 1.026-1.136, p = 0.003]. This model was an adequate fit to the data (Hosmer and Lemeshow test non-significant) and a fair discriminator for chest wall pain (area under receiver-operating characteristic curve: 0.74). Using the multivariate logistic regression model, parameters for D(max)1cm(3) are provided, which predict <10% and <20% risks of >= Grade 2 chest wall pain for different tumour sizes. Conclusion: Grade 2 + chest wall pain is an uncommon side effect of lung SABR. Larger tumour size and increasing D(max)1cm(3) are significant predictors of >= Grade 2 chest wall pain. When planning lung SABR, it is prudent to try to avoid hot volumes in the chest wall, particularly for larger tumours. Advances in knowledge: This article demonstrates that Grade 2 or greater chest wall pain following lung SABR is more common when the tumour is larger in size and the D(max)1cm(3) of the chest wall is higher. When planning lung SABR, the risk of chest wall pain may be reduced if maximum doses are minimized, particularly for larger tumours.